AbbVie Inc (ABBV)vsAirsculpt Technologies Inc (AIRS)
ABBV
AbbVie Inc
$203.89
+3.64%
HEALTHCARE · Cap: $360.63B
AIRS
Airsculpt Technologies Inc
$2.54
+2.83%
HEALTHCARE · Cap: $174.25M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 40185% more annual revenue ($61.16B vs $151.82M). ABBV leads profitability with a 6.9% profit margin vs -7.7%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
AIRS
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$203.89
$40.47 premium
Margin of Safety
+69.9%
Fair Value
$7.04
Current Price
$2.54
$4.50 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Earnings expanding 200.0% YoY
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
ROE of -14.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : AIRS
The strongest argument for AIRS centers on EPS Growth, Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : AIRS
The primary concerns for AIRS are Market Cap, Debt/Equity, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while AIRS is a turnaround play — different risk/reward profiles.
AIRS carries more volatility with a beta of 2.27 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 36/100). AIRS offers better value entry with a 69.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Airsculpt Technologies Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Airsculpt Technologies Inc (AIRS) is a leader in the aesthetic medical technology field, recognized for its proprietary AirSculpt® procedure, which offers minimally invasive body contouring solutions while emphasizing patient safety and comfort. The company boasts a growing network of licensed practitioners and a strong focus on technological innovation, positioning itself advantageously in the expanding market for non-invasive cosmetic treatments. By responding to the rising global demand for aesthetic procedures, Airsculpt aims to enhance its market share and diversify its service offerings, thereby fostering both immediate growth and sustainable long-term value for investors.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?